- cafead   Apr 11, 2024 at 12:12: PM
via Novartis is adding another weapon to its arsenal of oncology therapies, paying Arvinas $150 million upfront for rights to a phase 3-ready protein degrader that could treat a wide range of prostate cancer patients.
article source
article source